Strumento inattivo

Altre lingue Tiziana Life London S.E.

Azioni

TILS

GB00BKWNZY55

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

MEDIA: MS News Today: Foralumab found to ease fatigue in SPMS patients in access program	25/04
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	25/04
Sector Update: Health Care Stocks Rise in Afternoon Trading	23/04
Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program	23/04
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program	23/04
Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program	23/04
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today	22/04
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program	22/04
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program	22/04
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	19/04
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®	19/04
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology	19/04
Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	18/04
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	11/04
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease	05/03
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	08/01
Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	08/01
Tiziana Life Sciences Seeks Patent for Combination Therapy for Inflammation Linked to Type 2 Diabetes, Obesity	05/01
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024	05/01
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation	05/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Tiziana Life London S.E.

Azioni

TILS

GB00BKWNZY55

Altre lingue

Filtri